IQVIA has announced a major strategic collaboration with Amazon Web Services (AWS), naming the cloud company as its Preferred Agentic Cloud Provider—a move set to accelerate the digital transformation of the global life sciences and healthcare sectors. The partnership, unveiled at AWS re:Invent, aims to harness the power of agentic artificial intelligence to automate clinical trials, modernize medical affairs operations and advance next-generation analytics.
The initiative positions IQVIA’s AI platform at the heart of a new era in clinical research and healthcare data intelligence. By deploying the platform on AWS infrastructure, IQVIA expects to significantly enhance scalable and secure automation across key areas such as clinical trial execution, medical affairs processes and healthcare analytics. The collaboration will also explore novel use cases designed to fuel advanced insights and data-driven solutions across the life sciences industry.
IQVIA and AWS already hold strong ties with the global pharmaceutical landscape—90% of the world’s largest pharmaceutical companies rely on both organizations to support critical digital transformation and analytics efforts. With this partnership, the companies seek to democratize AI technologies across the sector, enabling faster innovation cycles, streamlined trial operations and accelerated delivery of life-saving treatments to patients worldwide.
Lucas Glass, senior vice president of Architecture and Standards at IQVIA, emphasized the transformative potential of the collaboration. “We are excited to move forward with AWS as IQVIA’s Preferred Agentic Cloud Provider. Our AI platform aims to empower life sciences organizations to innovate faster and deliver treatments to patients more efficiently. With agentic AI, we will unlock new possibilities for our clients and the industry at large,” he said.
Agentic AI—an emerging model in which AI systems can autonomously perform multi-step tasks, make decisions and adapt intelligently—stands at the center of the companies’ shared vision. By integrating these capabilities into key clinical and operational workflows, IQVIA aims to reduce trial bottlenecks, increase efficiency and enhance the reliability of insights across the drug development lifecycle.
AWS echoed this optimism. “We are thrilled to support IQVIA’s Agentic AI platform with the full breadth of AWS’s cloud capabilities,” said Allyson Fryhoff, director of Global Healthcare and Life Sciences at AWS. “Together, we aim to help the life sciences industry leverage the power of AI to support ongoing innovation in healthcare and achieve outcomes once thought impossible.”
The collaboration marks a notable advancement in the use of intelligent, cloud-driven technologies in life sciences. As pharmaceutical companies continue to navigate the complexity of clinical development, regulatory demands and global health challenges, IQVIA and AWS aim to provide tools that not only streamline operations but also meaningfully improve patient outcomes.
By combining AWS’s global cloud infrastructure with IQVIA’s deep expertise in clinical intelligence, the companies are positioning themselves to lead the next chapter of AI-driven transformation across healthcare and life sciences—one in which automation, insight generation and operational precision could become the new industry standard.